Treatment of refractory complex partial seizures: role of vigabatrin by Waterhouse, Elizabeth J et al.
© 2009 Waterhouse et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment
Neuropsychiatric Disease and Treatment 2009:5 505–515 505
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
e x P e rT   O P i N i O N
Treatment of refractory complex partial seizures: 
role of vigabatrin
elizabeth J Waterhouse 
Kimberly N Mims 
Soundarya N Gowda
Department of Neurology,   Virginia 
Commonwealth University School 
of Medicine, richmond,   VA, USA
Correspondence: elizabeth J Waterhouse 
Department of Neurology,   Virginia 
Commonwealth University School of 
Medicine, 1101 e. Marshall St., PO Box 
980599, richmond,   VA 23298, USA 
email ewaterhouse@mcvh-vcu.edu
Abstract: Vigabatrin (VGB) is an antiepileptic drug that was designed to inhibit 
GABA-transaminase, and increase levels of γ-amino-butyric acid (GABA), a major inhibitory 
neurotransmitter in the brain. VGB has demonstrated efficacy as an adjunctive antiepileptic 
drug for refractory complex partial seizures (CPS) and for infantile spasms (IS). This review 
focuses on its use for complex partial seizures. Although VGB is well tolerated, there have 
been significant safety concerns about intramyelinic edema and visual field defects. VGB is 
associated with a risk of developing bilateral concentric visual field defects. Therefore, the use 
of VGB for complex partial seizures should be limited to those patients with seizures refractory 
to other treatments. Patients must have baseline and follow-up monitoring of visual fields, early 
assessment of its efficacy, and ongoing evaluation of the benefits and risks of VGB therapy.
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Introduction
The discovery of γ-aminobutyric acid (GABA) as the first major inhibitory 
neurotransmitter, and a program exploring the use of enzyme inhibition as a therapeutic 
tool provided the basis for the conception of vigabatrin (VGB). VGB was first approved 
in the United Kingdom in 1989, and is used in over 50 countries as an adjunctive therapy 
of adult patients with refractory complex partial seizures (CPS), and as a treatment for 
patients with infantile spasms (IS). This review focuses on its use for CPS. VGB has 
not been available in the United States, due to concerns about its safety. After further 
analysis of data regarding adverse effects and safety, clinical monitoring guidelines 
are being developed to reduce the potential risks associated with its use in patients 
with these severe epileptic conditions.
Pharmacology
The VGB molecule, a structural analog of GABA, was designed to have enzyme-
activated highly specific activity as an irreversible inhibitor of GABA-transaminase. 
Vigabatrin (4-amino-5-hexenoic acid, or γ-vinyl GABA) was first synthesized in 
1977 as a selective irreversible inhibitor of gamma-aminobutyric acid transaminase 
(GABA-T).1 By inhibiting GABA-T, the enzyme responsible for the catabolism of 
GABA, VGB increases whole brain levels of GABA, leading to a reduction in seizure 
activity.
The molecular structure of VGB is shown in Figure 1. VGB is a racemic compound 
and its [S]-enantiomer is pharmacologically active.2,3 When administered orally, 
VGB is rapidly and near-completely absorbed and has dose-proportional and linear Neuropsychiatric Disease and Treatment 2009:5 506
Waterhouse et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
pharmacokinetics. VGB is completely absorbed following 
oral administration and can be given without regard to meals.4 
After administration, peak VGB concentration occurs within 
2 hours.5 It is widely distributed with a volume of distribution 
steady-state of 1.1 L/kg and does not bind to plasma proteins. 
VGB is not metabolized and is eliminated unchanged by 
renal excretion.6
The T1/2 of VGB is approximately 5 to 7 hours; however 
plasma levels are not correlated with clinical effect.7 A study 
of patients with epilepsy given single oral dose of VGB 
found that peak levels were achieved in less than 1 hour in 
the serum, and 6 hours in the CSF. GABA levels remained 
elevated in the CSF for over 1 week.8 The duration of the 
clinical effect of VGB is thought to be dependent on the 
rate of GABA-T resynthesis rather than on the plasma 
concentration of VGB. The rate of recovery of GABA-T 
is 5 days.1
In vitro metabolism studies show that there is a low 
potential for drug-drug interactions with VGB due to 
enzyme induction of CYP2B6 or CYP3A4.9 However, in 
some clinical studies, VGB was associated with modest 
decreases in plasma phenytoin levels.10,11 The cause of these 
findings is unclear, as VGB is not protein bound, and is not 
metabolized.12 A mild increase in carbamazepine (CBZ) 
levels in patients receiving adjunctive VGB has also been 
reported.13 These findings suggest that levels of concomitant 
antiepileptic drugs should be monitored, but dose adjustment 
is usually unnecessary.
Vigabatrin and infantile spasms
Although VGB plays an important role in the treatment 
of IS, a comprehensive review of its efficacy for spasms 
is beyond the scope of this article. In brief, investigators 
have reported cessation of infantile spasms in 16% to 76% 
of patients with IS.14,15 Studies have been complicated by 
methodological issues, including the ethics of administering 
a placebo, and the challenge of accurately documenting 
outcomes in a condition that causes numerous brief spasms 
daily. Evidence suggests that hormonal treatment achieves 
spasm resolution more quickly and in more infants than 
VGB treatment.16 However, VGB may be the treatment of 
choice for IS due to tuberous sclerosis.16 A meta-analysis of 
studies assessing the efficacy of VGB for IS found that 95% 
of patients with tuberous sclerosis achieved freedom from 
spasms, while the rate was 54% for patients without tuberous 
sclerosis.17 A 2009 long-term follow-up study comparing 
VGB and ACTH treatment in 28 patients with idiopathic 
West Syndrome found no significant difference in short-term 
seizure response (80 and 88%, respectively), although ACTH 
was associated with better long-term cognitive outcome.18
Efficacy of vigabatrin for refractory 
complex partial seizures
A number of well designed trials have found VGB effective as 
adjunctive therapy in patients with refractory complex partial 
seizures. Responder rates (50% seizure reduction) have 
varied according to study design and VGB dose. A review 
of double-blind, placebo-controlled studies of adjunctive 
therapy with newer antiepileptic drugs reported that the 
overall responder rate for VGB 3 g daily was 44.2%, and 
the placebo responder rate was 13.8%.19
In the 1980s, several double-blind, placebo-controlled 
crossover design studies of VGB as adjunctive treatment 
for partial seizures were performed, demonstrating 
responder rates ranging from 33% to 67% with doses of 
2 to 3 g daily.11,20–23 The variability of responder rates is 
likely due several factors: the small number of patients 
analyzed, and the inclusion, in some studies, of generalized 
seizures.11,23 A larger, similarly designed 1996 Australian 
study of 97 patients with uncontrolled CPS found a 
responder rate of 42%.24
A single-blind, placebo-controlled, multicenter trial of 
VGB was carried out in 101 patients with epilepsy, most 
of whom had refractory partial seizures. The inclusion of 
patients with other types of epilepsy may have contributed 
to the 11% drop-out rate, which was primarily due to 
increased seizure frequency. Among those completing the 
trial, the median number of monthly seizures decreased 
from 16 during the placebo phase to 5 during the final 
8 weeks of treatment. A greater than 50% reduction in 
seizure frequency (compared to placebo) was observed in 
60 patients.25
A Canadian multicenter, double-blind, placebo-controlled 
parallel group trial of VGB in patients with refractory com-
plex partial seizures and/or partial seizures with secondary 
generalization included 111 patients. The responder rate 
was 48% for VGB in doses up to 4 g daily, and 26% for 
placebo.26
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Figure 1 Molecular structure of the vigabatrin molecule.Neuropsychiatric Disease and Treatment 2009:5 507
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Two large trials of VGB for refractory complex partial 
seizures have been carried out in the US. The studies enrolled 
patients 18 to 60 years old, with an average 22-year history 
of epilepsy. Patients were taking 1 or 2 concomitant antiepi-
leptic drugs (AEDs) at the time of entry into the studies. In 
both trials, a parallel group design was used, and the primary 
endpoint for efficacy was change in median monthly seizure 
frequency, compared to baseline, during the final 8 weeks 
of the study.
The study by French et al analyzed 182 patients taking 
either adjunctive VGB 3 g daily or placebo. VGB signif-
icantly decreased baseline monthly seizure frequency 
(–3.0) compared with placebo (–0.8), and 5.4% of the VGB 
patients became seizure free, while none of the placebo-
treated patients achieved seizure freedom. The responder 
rate (50% reduction from baseline seizure frequency) was 
43% for VGB and 19% for placebo. Statistically significant 
seizure reduction occurred early, after 2 weeks of VGB 
therapy, and was maintained during the 16-week treat-
ment phase.27
A second US placebo-controlled, randomized, double-
blind, multicenter study examined the efficacy and safety 
of 3 daily doses of VGB (1, 3, or 6 g) as add-on therapy in 
174 patients with previously uncontrolled complex partial 
seizures. The responder rates were 7% for placebo and 
24%, 51%, and 54% for patients taking daily VGB doses 
of 1, 3, and 6 g, respectively. Seizure freedom occurred 
in 9.5 % of those taking 3 g daily, 12.2% of those taking 
6 g daily, and none of those taking 1 g daily or placebo. 
As in the earlier study, seizure reduction was evident after 
2 weeks of therapy (at the 3 and 6 g daily doses), and was 
maintained during the remainder of the study. There was no 
statistically significant difference in efficacy between the 
3 and 6 g regimens.28
Adjunctive VGB therapy is effective for children with 
partial seizures. A prospective study including 178 patients 
with refractory partial seizures, aged 1 week to 19 years, 
found a 70% responder rate, and a 30% seizure freedom 
rate. Those with tuberous sclerosis had a particularly robust 
responder rate of 85%.29 These responder rates are higher 
than the rates reported for adults. The authors attribute the 
high efficacy rate to the fact that infants made up 22% of their 
study population, and infants responded better than older 
children to VGB. However, the inclusion of single-blind and 
open-label cohorts may also have introduced bias in favor of 
VGB treatment. A recent retrospective study reported a 34% 
responder rate in 59 infants and children with partial seizures, 
including 17% who became seizure free on VGB.30
To summarize, VGB has demonstrated significant 
efficacy as adjunctive therapy for patients with poorly 
controlled partial epilepsy, refractory to other antiepileptic 
drugs. Differences in inclusion criteria (especially type of 
epilepsy), VGB dosing, study population size and charac-
teristics, and study design contribute to the variability of 
the reported response rates (approximately 40% to 60%). 
A meta-analysis of key clinical trials for 5 newer AEDs 
found that VGB had the most favorable improvement 
rates (responder rate minus placebo response) at recom-
mended doses.19 Thus, adjunctive treatment with VGB is 
an appropriate consideration for patients who have failed 
treatment with available AEDs, have poor quality of life due 
to frequent complex partial seizures, and will comply with 
monitoring of for adverse effects. The potential for seizure 
reduction must be weighed against safety risks, which will 
be reviewed below.
Vigabatrin monotherapy studies
Several studies have evaluated vigabatrin as monotherapy, 
compared with carbamazepine (CBZ). The results suggest 
that VGB is the less effective, but better tolerated, of the 
2 drugs. An open-label, randomized controlled study 
evaluated the efficacy, safety and cognitive effects of 
initial VGB monotherapy compared to initial CBZ 
monotherapy in patients with newly diagnosed epilepsy. 
A total of 100 patients, aged 15 to 64 years, with partial 
seizures and/or generalized tonic-clonic seizures were 
randomized to receive either VGB (mean dose 50 mg/kg), 
or CBZ (titrated to plasma concentrations of 35 µmol/L) for 
1 year. The primary outcome measure was the proportion 
of patients continuing successful treatment, and was 60% 
for both drugs, but this number reflects a broad definition 
of treatment success, which included “acceptable seizure 
control” in addition to seizure freedom. It is debatable 
whether the definition of acceptable seizure control (1 to 4 
partial seizures and no more than 1 generalized seizure 
during a treatment period) is appropriate for patients 
with newly diagnosed epilepsy. Seizure freedom rates 
significantly differed between the groups: 52% for the CBZ 
group, and 32% for the VGB group. Although VGB had to 
be discontinued in some patients due to lack of efficacy, 
none discontinued due to adverse effects. In contrast, 24% 
of the CBZ group discontinued treatment due to adverse 
effects, primarily rash.31
Similar findings of relatively lower efficacy but better 
tolerability of VGB occurred in a randomized crossover 
study comparing CBZ and VGB in 51 patients with newly Neuropsychiatric Disease and Treatment 2009:5 508
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diagnosed partial epilepsy. In this study, patients started on 
either 200 mg daily of CBZ or 1 g daily of VGB, and the 
doses were increased weekly until seizures ceased or intol-
erable side effects occurred. Seizure-free rates were 56% 
and 46% for CBZ and VGB respectively. Those patients 
with persistent seizures or intolerable side effects entered 
the cross-over phase, and received the other drug. Of the 
crossover patients, 43% receiving CBZ and 45% receiving 
VGB achieved seizure freedom. Considering both phases 
together, 51% of CBZ patients and 46% of VGB patients 
had seizure freedom and acceptable tolerance. Differences 
in efficacy were not statistically significant. Side effects were 
more frequent in the CBZ group (41%) compared with the 
VGB group (22%), but this difference was not statistically 
significant. The most frequent complaint was drowsiness, 
and fewer side effects occurred with VGB.32
The largest monotherapy study involved 459 patients, 
aged 12 to 65 years, with previously untreated newly 
diagnosed partial seizures, randomized to monotherapy 
with either CBZ 600 mg daily or VGB 2 g daily. Patients 
had had at least 2 seizures in the previous year, includ-
ing simple or complex partial seizures, with or without 
secondary generalization. The primary outcome was time 
to withdrawal from drug, a measure that encompasses 
efficacy and tolerability, and the CBZ and VGB groups 
did not significantly differ on this measure. Secondary 
outcomes included additional efficacy and tolerability 
parameters. Efficacy outcomes favored CBZ, with a sig-
nificant difference in time to first seizure. At 1 year, 58% 
of CBZ-treated patients and 38% of VGB-treated patients 
remained seizure-free. VGB was better tolerated than CBZ, 
with significantly fewer VG patients withdrawing due to 
adverse effects (19% VGB vs 27% CBZ at 1 year). Patients 
reported drowsiness, fatigue, headache, and dizziness with 
each of the drugs. VGB was more frequently associated 
with weight gain and psychiatric symptoms, most com-
monly depression.33
The results of these monotherapy trials consistently 
demonstrate that, in terms of efficacy, VGB is inferior to 
CBZ in patients with newly diagnosed partial onset epilepsy. 
VGB is not recommended for use as monotherapy in this 
clinical setting.
Seizure type
Limited data suggest that VGB is more effective for CPS 
than for generalized seizures. In general, few patients with 
primary generalized epilepsy or symptomatic generalized 
epilepsies were included in studies, and analysis has been 
hampered by variability in the diagnostic labels used by 
various authors. A review of 487 patients treated with 
VGB from published clinical trials included 52 patients 
with generalized seizures, including tonic-clonic, juvenile 
myoclonic epilepsy, Lennox-Gastaut syndrome, Ramsay-Hunt 
syndrome, absence, myoclonic seizures, symptomatic or 
secondary generalized epilepsies, and generalized seizures of 
unspecified type. The responder rate (at least a 50% decrease 
in seizure frequency) was 21% for these patients, while 46% 
were unchanged, and 25% were worse. The authors note 
that those with secondary generalized epilepsy had the worst 
response. In comparison, the VGB responder rate for patients 
from the same studies with CPS, with or without secondary 
generalization, was 49%.34
Long-term follow-up
Several studies examining long-term follow-up have found that 
those patients whose seizures improved during initial treatment 
with VGB continued to show significant benefit 1–5 years 
later.35,36 Two small case series following VGB-treated 
refractory epilepsy patients for 6 to 10 years suggest that 
epilepsy may improve with continued VGB treatment, with 
some patients becoming seizure free over time.37,38
Tolerability of vigabatrin
In general, VGB is well tolerated, with side effects that are 
frequently seen in the setting of AED therapy. When data 
were pooled from controlled trials in epilepsy patients, 
excluding those with IS, there were 588 patients on VGB 
and 373 taking placebo. The most frequent side effects 
were fatigue (VGB 22.3%, placebo 15.3%), dizziness (VGB 
18.9%, placebo 15.6%), somnolence (VGB 16.3%, placebo 
9.9%), and increased weight (VGB 11.1%, placebo 7.2%).6 
Among these patients, 15% of those treated with VGB 
discontinued their participation in a study due to an adverse 
event, compared with 4.6% of the patients receiving placebo. 
The most common symptoms leading to discontinuation 
in the VGB treatment group were depression (VGB 1.7%, 
placebo 0.5%), convulsion (VGB 1.2%, placebo 0.5%), 
disturbance in attention (VGB 1.0%, placebo 0.5%), head-
ache (VGB 1%, placebo 0.5%), and agitation (VGB 1.0%, 
placebo 0%).6
Weight gain occurs more frequently in epilepsy patients 
treated with VGB, compared with placebo.33,35,37 In a 
monotherapy study, 11% of VGB patients gained weight, 
compared with 5% of those treated with CBZ.33 The degree 
of weight gain is variable, averaging 3.7 kg ± 0.2 kg in 
a long-term study of adjunctive treatment with VGB.39 Neuropsychiatric Disease and Treatment 2009:5 509
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Another long-term follow-up study of 25 VGB responders 
found increases of 5–16% of initial body weight in 10 
of the patients. Weight gain in these patients tended to 
occur after 3 to 6 months on VGB, and plateaued within 
several months.40
Cognitive and psychiatric side effects
Cognitive side effects are an important concern of patients 
with refractory CPS, and VGB has little effect on cognitive 
function.31,41–43 Although participants in one study reported 
sedation early in the course of treatment, the VGB responders 
showed significant improvement in composite scales of 
psychomotor function, memory, and self-rating.42 A battery 
of 8 standardized cognitive tests found a significant 
difference between the VGB and placebo groups only on the 
Digit Cancellation Test. Scores on this test decreased with 
increasing dose of VGB.44 A randomized, placebo-controlled, 
parallel-group study of VGB adjunctive therapy in 45 patients 
found a small but statistically significant reduction in motor 
speed, and a modest impairment of performance on a visual 
memory task.45
The potential for psychiatric side effects with VGB 
treatment has been under scrutiny since an early report 
of 14 cases of psychosis among 210 patients treated with 
VGB.46 Further studies have found a lower incidence of 
these symptoms. A 1996 literature review of controlled trials 
reported an incidence of severe abnormal behavior in 3.4% 
of adults treated with VGB.47 Pooled data from controlled 
studies of epilepsy patients, excluding those with IS, indicate 
that 7.8% of those on VGB had depression, and 5.4% 
reported confusional state, compared with 4.6% and 1.6%, 
respectively, in placebo-treated patients.6 A meta-analysis of 
data from placebo-controlled trials of adjunctive therapy with 
VGB found that the incidence of psychotic events with VGB 
was 2.5%, vs 0.3% with placebo.48 In smaller monotherapy 
trials, psychosis was not reported.31,32 In a larger mono-
therapy trial, 25% of patients taking VGB had psychiatric 
side effects, described as agitation, depression, insomnia, or 
“other,” compared with 15% of those taking CBZ.33
VGB is one of several antiepileptic drugs associated 
with depression.49 French et al reported depression in 12% 
of patients titrated to 3 g VGB daily, compared with 3% of 
patients receiving placebo.27 These findings are comparable to 
the results of a meta-analysis, which showed an overall inci-
dence of depression of 12.1% in patients treated adjunctively 
with VGB, compared to 3.5% with placebo.48 The incidence 
of depression is lower, about 6%, with VGB monotherapy.33 
Depression in the setting of VGB treatment is typically 
mild. In general, psychiatric side effects decrease with dose 
reduction or slow taper of VGB, and typically reverse with 
discontinuation of VGB.14,48
Safety issues
In addition to the side effects reported by patients, there are 
two safety issues that have been extensively investigated: 
intramyelinic edema (IME) and visual field defects.
intramyelinic edema
IME was initially reported in rodents and dogs treated with 
VGB.50 In rats, myelin microvacuolation leading to IME 
was localized to the hypothalamus, fornix columns, and 
cerebellar white matter, while in dogs it was found in the 
hypothalamus, fornix columns, optic tract and chiasm.51 
In another study, VGB caused dose- and time-dependent 
microvacuolation within white matter tracts of the cerebellum, 
reticular formation and thalamus in rodents, and the fornix 
and anterior commissure in dogs.52 On electron microscopy, 
the microvacuolation was caused by separation of the outer 
lamellar sheaths of myelinated fibers and has been termed 
IME. The edema developed over a period of several weeks, 
after which a relative plateau was reached. It was reversible in 
both rats and dogs 12 to16 weeks after stopping VGB. Dogs 
did not have any residual pathology after recovery, but rodents 
retained swollen axons and foci of microscopic mineralization 
within the cerebellum after recovery. Monkeys were studied, 
but did not demonstrate any conclusive pathological changes.52 
Because the inactive R-enantiomer of VGB is not associated 
with IME, while the active S form is, IME is thought to be 
related to higher levels of brain GABA.6,52
Human trials of VGB were suspended in 1983 in the US 
due to the recognition of IME in rodents and dogs. Evoked 
potential studies and MRI proved to be sensitive non-invasive 
techniques to diagnose IME in these animals, and to confirm 
its absence in humans and other primates. Clinical trials were 
allowed to resume in 1990 after review of additional data.6 
Autopsy and surgical brain specimens failed to show evidence 
of IME in children or adults with complex partial seizures.53 
MRI was also normal in humans treated with VGB in doses 
from 1 to 6 g per day for 3 months to 12 years. A review of 
data from 350,000 patient-years of VGB exposure found no 
definite case of VGB-induced IME.54
The assumption that IME is a species-specific adverse 
effect of VGB not affecting humans was called into question 
in 2006, when MRI signal changes consistent with IME were 
reported in infants with IS, treated with VGB.55 A follow-up 
study reported MRI T2 hyperintensities in the basal ganglia, Neuropsychiatric Disease and Treatment 2009:5 510
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thalami, anterior commissure and corpus callosum in 7 out 
of 22 patients, ranging in age from 3 months to 18 years, 
all of whom were treated for IS.55 In all of the patients, the 
T2 hyperintensities resolved with discontinuation of the 
medication.
Subsequent studies have confirmed MRI signal 
changes associated with VGB in infants.56,57 Wheless et al 
retrospectively reviewed MRI findings in VGB-treated 
patients, including 205 infants with IS, and a group of 
668 patients (children over the age of 2 years, and adults) 
with refractory CPS.56 A statistically significant increase 
of pre-specified MRI abnormalities occurred only in the 
infants with IS treated with VGB. The prevalence of MRI 
abnormalities was 22% in the VGB-treated infants, com-
pared with 4% for VGB-naïve infants, while no statistically 
significant difference occurred in those treated for CPS.56 
VGB-associated MRI changes in infants may not be lim-
ited to those with IS; they have also been described in a 
small number of infants with focal epilepsy and epileptic 
encephalopathy.57
MRI abnormalities associated with VGB in infants have 
typical characteristics. They are best seen on T2-weighted, 
FLAIR and diffusion-weighted images, and occur pre-
dominantly in the basal ganglia, thalamus, brainstem, or 
cerebellum.56 They tend to peak after 3 to 6 months of 
exposure to VGB and most resolve, even with continued 
use of VGB.56,57 Although VGB is associated with a risk of 
MRI abnormalities in infants, there is no evidence for MRI 
changes due to VGB in children or adults with refractory 
CPS.56 Investigators have hypothesized that developmental 
changes in myelination in infants, or an underlying metabolic 
condition, may predispose infants, but not older individuals, 
to VGB-induced MRI changes.56
Visual field defect
The most significant and unique VGB-specific side effect is a 
peripheral visual field defect, occurring in one third or more 
of patients treated with VGB.58 Rare sporadic visual field 
defects were reported during VGB development. In 1997, 
Eke et al published 3 case reports describing severe persis-
tent peripheral visual field loss in patients who had been on 
VGB for over 2 years.59 The patients presented with “tunnel 
vision” and one presented after noticing increased frequency 
of bumping into objects after 2 to 3 years on VGB. Eke’s 
report was followed by several case series documenting 
visual field defects in the setting of VGB adjunctive therapy. 
A troubling finding was that visual field defects frequently 
were asymptomatic. Patients did not recognize that their 
visual fields were impaired. Even patients with severe visual 
impairments sometimes attributed the difficulties that they 
experienced to clumsiness or drowsiness, and the nature of 
the problem was not clarified until visual field testing was 
performed.58 These difficulties in reporting and diagnosing 
visual field defects led to delayed recognition of this problem 
as an adverse effect of VGB, and under-estimation of the risk 
in early studies. The median time to onset of the first obser-
vation of bilateral concentric peripheral field constriction in 
patients with CPS was over 4 years.6
The peripheral visual field defect typically begins as a 
bilateral nasal defect, and progresses to bilateral concentric 
field constriction (see Figure 2). Initially, the visual defect 
is asymptomatic and is detected only by static or kinetic 
Figure 2 Humphrey visual field map of a patient treated with vigabatrin (VGB).   While the visual field defect in patients treated with VGB is typically similar in both eyes, in 
this patient, the right eye has restriction of the nasal field, while the left eye is more severely affected, demonstrating concentric restriction.Neuropsychiatric Disease and Treatment 2009:5 511
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perimetry or electroretinogram (ERG). The earliest detectable 
visual field deficit is usually peripheral field depressions that 
later increase centripetally and rarely progress centrally.60 
It is hypothesized that patients do not notice the decreased 
peripheral vision loss early in the course of treatment because 
the initial peripheral vision loss occurs nasally and the bin-
ocularity of human vision compensates for nasal visual field 
loss. Symptomatic patients tend to have bilateral concentric 
field constriction, with involvement of their temporal visual 
fields, which are more likely to affect daily function since 
there is no visual field overlap temporally.6 VGB exposure 
has not been shown to cause significant problems with central 
visual acuity.
Pathophysiology of VGB-associated  
visual field defect
Although the pathophysiology of VGB-induced visual 
field defects is not entirely clear, animal studies have 
characterized retinal changes. Albino rats demonstrate 
dose-dependent concentration of VGB in the outer retina 
and also demonstrate retinal degeneration.61 The retinal 
changes occur in the periphery and involve the outer nuclear 
layer, with displacement of the nuclei into the rod layer. 
VGB itself accumulates in the retina in significantly higher 
concentrations relative to other tissues, and is associated with 
accumulation of GABA in the retina.62 In the setting of VGB 
treatment, animal studies demonstrate decreased activity 
of glutamic acid decarboxylase and GABA transaminase 
activity, and accumulation of GABA in the retina. Wang 
et al hypothesize that VGB may be associated with impaired 
glutamate release, based on abnormal retinal synaptic 
plasticity seen on examination of retinal tissue of albino 
mice treated with VGB.63
A recent study suggests that light exposure and taurine 
deficiency may contribute to retinal damage and peripheral 
field defects in the setting of VGB treatment.64 In this 
study, VGB-treated rats exposed to cycles of 12 hours of 
light and 12 hours of darkness exhibited more pronounced 
retinal lesions than those kept in darkness alone. It was also 
noted that taurine levels were 67% lower in VGB-treated 
animals compared with control animals, and taurine 
levels correlated with ERG amplitudes. Although dietary 
taurine supplementation did not reverse existing retinal 
changes, it reduced the development of retinal damage. 
The study suggests that, in rats, VGB induces a deficiency 
in taurine, resulting in retinal phototoxicity.64 To assess 
the potential relevance of these findings to humans, the 
authors retrospectively reviewed data for 6 VGB-treated 
infants with infantile spasms. Five of the infants had low 
or undetectable taurine levels, including one who had a 
normal level prior to VGB treatment.64
risk factors for the development  
of visual field defects
Visual field defects occur in a significant number of patients 
treated with VGB, but studies of the prevalence and risk 
factors for VGB-associated visual field defects have reported 
widely varying results due to a variety of factors. These 
include the retrospective nature of the studies, the small 
numbers of patients studied, the lack of patient symptoms, 
the long latency until the condition was recognized and 
characterized by clinicians, and the variety of visual testing 
techniques used.65 Reviewing 11 studies, Kalviainen et al58 
found an overall prevalence of bilateral concentric visual 
field defects in 32% of 528 patients treated with VGB. 
In 22 studies reviewed by Kinirons et al66 peripheral visual 
field constriction occurred in 19% to 92% of  adults with 
CPS treated with VGB, and up to 31% of infants with 
infantile spasms. In most of these studies, VGB was used 
as an adjunctive antiepileptic drug. VGB-associated visual 
field deficit has also been seen in patients treated with 
monotherapy. A study of newly diagnosed epilepsy patients 
who had been randomized to monotherapy with either VGB 
or CBZ, found that 41% of the 32 patients receiving VGB 
had visual field constriction, while none of the 18 patients 
receiving CBZ was affected.67
It is unclear why some patients develop peripheral visual 
field defects on VGB and others do not. Studies suggest that 
males have twice the risk of developing a visual field defect 
from VGB compared to females.58,68–72 Smoking has also 
been reported as a risk factor.6,58 However, a cohort study 
of 93 patients did not identify increased risk due to these 
factors.73
There are contradictory reports regarding the risk of 
visual field defect and its relationship to cumulative exposure 
to VGB, maximum dose, and duration of dose. Several 
studies did not find evidence that these parameters correlated 
with the development of visual field defects.58,68,73 However, 
a cohort study of the cumulative incidence of visual field 
defects and cumulative VGB dose in 291 patients found 
that the cumulative incidence of visual field defects rapidly 
increased within the first 2 kg of VGB intake, and stabilized 
after a total of 3 kg of VGB.69 Conway et al74 suggest that 
maximum daily VGB dose is a predictor for development of 
peripheral visual field defects, and not cumulative or duration 
of dose.74 Other studies have also suggested that degree or Neuropsychiatric Disease and Treatment 2009:5 512
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duration of VGB exposure correlate with the development 
of peripheral visual field defects.60,75–80
Visual field defects in children
Although some studies have suggested that children treated 
with VGB are less likely then adults to develop visual field 
defects, a recent study found only a small difference between 
children 8 to 12 years of age and older study participants. The 
proportion of patients with visual field defects was 29% for 
those 8 to 12 years of age, and 33% for those over age 12. 
This difference was not statistically significant, possibly 
due to the small size of the comparison groups.65 The risk of 
VGB-associated visual field abnormalities may be lower in 
children who were treated with VGB in infancy, compared 
to those who received it later in childhood. Mild visual field 
loss was found in 1 of 16 children, aged 6 to 12 years, who 
had been treated with VGB during infancy for IS.81
Time course of visual field defect
Analyses of the time course of peripheral visual field defects 
with VGB suggest that it develops gradually. Ovation Phar-
maceuticals reports that, in patients with CPS on VGB, 
the earliest documented peripheral visual defect occurred 
after 9 months of treatment in adults, and after 11 months 
in children.6 There is a case report of a visual field defect 
developing within 6 months of VGB treatment.82 After 5 years 
of VGB treatment, the risk of development of peripheral 
visual field defect decreases sharply.73
Although varying methods of testing and the variability 
of patient responses make it difficult to combine study 
results, on average the progression of the visual field 
defect is 2 degrees per year from the temporal visual 
field and 1 degree per year in the nasal field.6 Once the 
peripheral visual fields are affected, the defect is usually 
irreversible but does not worsen over time.70,83 In a study 
of 60 adults with CPS treated with VGB for up to 14 years, 
40% had visual field defects. At follow-up, after an average 
of 15 months, there was no significant progression in patients 
who continued to take VGB and no recovery in those who 
had discontinued it. Ovation Pharmaceuticals reported 1 
patient who had progression of his visual field defect 4 years 
after discontinuing VGB.6
Diagnostic testing of visual fields
Several options are available to test for visual field defects. 
The only method appropriate for testing infants, young 
children, and adults unable to cooperate with visual field 
testing is the ERG, during which an electrode is placed on the 
eye to monitor the response of the retina to flashes of light. 
Although the ERG is not a direct test of visual fields, wide-
field and multifocal ERG techniques are highly sensitive at 
detecting VGB-associated retinal pathology.84–86 Perimetry 
techniques require patient cooperation. Kinetic perimetry, 
of which the most commonly performed is Goldmann 
perimetry, consists of an examiner moving stimuli through 
the patient’s peripheral visual field and mapping defects 
on a reference grid. Static perimetry uses automated visual 
field analyzers, such as the Humphrey visual field analyzer, 
to determine the threshold intensity that the patient can 
perceive at specific locations in the visual field. The patient’s 
reaction is then measured and mapped to display the visual 
field. Routine visual evoked potentials (VEPs) are not useful 
for assessing retinal changes, but field-specific VEPs have 
identified VGB-induced retinal defects in children over 
2 years of age.87
A “gold standard” test for identifying VGB-associated 
visual field defects has not been established. Thus the true 
sensitivities and specificities of various techniques in this 
Table 1 recommendations for use of vigabatrin (VGB) in adults with complex partial seizures
Patient selection
  The patient has failed adequate trials of multiple antiepileptic drugs or therapies (ie, neurostimulation).
  The patient is not a candidate for resective epilepsy surgery.
  The patient and/or guardian understand the potential risks of treatment, give consent for treatment, and will be compliant with follow-up testing.
Patient monitoring
  The patient or care-giver should keep a seizure calendar at baseline and during treatment, in order to facilitate assessment of efficacy.
  Baseline visual field testing must be performed prior to starting VGB. Patients with pre-existing visual field defects should not receive VGB.
  After 12 weeks of treatment, seizure response to VGB should be assessed. If there has been no significant improvement,   VGB should be discontinued.
    If meaningful improvement in seizures has occurred with VGB treatment, treatment may be continued, with formal testing of visual fields or retinal 
function every 3 to 6 months.
  If there is evidence of visual impairment, the risks and benefits of   VGB treatment should be reconsidered in light of the individual’s circumstances.Neuropsychiatric Disease and Treatment 2009:5 513
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clinical setting cannot be calculated. In one study, objective 
outer limit testing (a “bedside” method performed by an 
examiner with a flashlight) detected 83% of the visual field 
defects identified by Goldmann perimetry, while manual 
kinetic perimetry detected 93%, and high pass resolution 
perimetry (a computer-based central field test) had a sensi-
tivity of 72%.60 In general, while ERG is the most specific 
test, both static and kinetic perimetry are believed to have 
adequate sensitivity to monitor peripheral vision with VGB.14 
As our knowledge of the pathophsyiology of the VGB field 
defect progresses, it is likely that the optimal strategy for 
visual testing will evolve.
A promising technique for identification of VGB-associated 
visual abnormalities involves imaging of the retinal nerve fiber 
layer. The characteristic pattern consists of thinning of the nasal 
quadrant but sparing of the temporal quadrant. This finding 
may precede visual field loss. A recent study that measured the 
thickness of the retinal nerve fiber layer using ocular coherence 
tomography found this pattern in all of the 11 patients with 
confirmed VGB-associated visual field deficits, as well as 4 of 
15 VGB-treated patients who had normal fields. These find-
ings suggest that nasal retinal nerve fiber layer attenuation is 
a promising biomarker for VGB toxicity, and may be valuable 
indicator for consideration of VGB withdrawal.88
Recommendations for visual field monitoring
All patients with refractory CPS who are considering 
treatment with VGB should have a baseline visual field 
examination. VGB should not be used in those with restricted 
visual fields at baseline. VGB-treated adults should have a 
follow-up visual field examination every 6 months. Infants 
should be tested at 3-month intervals for the first 18 months 
of treatment, and then every 6 months. It has been well 
documented that response of CPS to VGB is evident by the 
12th week of therapy, earlier than the reported onset of visual 
field defects.14 If substantial improvement in CPS has not 
been achieved by 12 weeks of VGB therapy, then the drug 
should be stopped in order to minimize the risk of developing 
a peripheral visual field defect. If VGB treatment is success-
ful in treating refractory CPS, the risks and benefits at that 
point should be re-evaluated with the patient. Data suggest 
that after 5 years of VGB exposure, the risk of developing 
a peripheral visual field defect stabilizes and therefore less 
intensive monitoring may suffice at that point.6
Conclusions and recommendations
Approximately 30% of patients with epilepsy have seizures 
that continue to occur despite pharmacologic treatment.89 
Uncontrolled seizures can severely impair a patient’s quality 
of life, and may lead to seizure-related injuries or even sudden 
unexplained death in epilepsy.90,91 Improvement in seizure 
control in this population can positively affect prognosis and 
patient well-being.
The major benefit of VGB is that it has demonstrated 
efficacy in some patients whose seizures have been resistant 
to other drugs. A comparison of key clinical trials of newer 
antiepileptic drugs found a favorable efficacy and side effect 
profile for VGB in the adjunctive treatment of CPS.19 It has 
few cognitive side effects, and is generally well tolerated 
by patients.
These potential benefits must be balanced with the signifi-
cant risk of developing a visual field defect, which develops 
in about one third of patients taking VGB. Because of this 
risk, VGB should be considered only as adjunctive therapy 
for those patients whose CPS have not responded to other 
treatments, and who are not appropriate candidates for other 
therapies, such as epilepsy surgery.92 Since the onset of visual 
field defects is usually asymptomatic, visual fields and/or 
ERG must be checked at baseline, and every 3–6 months 
during treatment, to monitor for the development of defects. 
General recommendations for patient selection and monitoring 
are listed in Table 1. A cautious strategy of targeted patient 
selection and careful monitoring for visual field defects should 
optimize the risk-benefit ratio of VGB in the clinical setting.
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